Shionogi Company Limited

B.r.a.h.m.s Gmbh

Shionigi & Co., Ltd.

Toshisada Yano

Hiromu Matsumura

Masami Eigyo

Akira Matsushita

Hiroshi Hashizume

Goro Katsuura

Mikio Hoshino

Isako Sakaguchi

Masayuki Narisada

Naoki Yoshikawa

Yasukazu Yamanaka

Toshiyuki Kanemasa

Shoichi Yamamoto

Nobuhiro Ibii

Teruo Shiomi

The present invention provides a rare earth metal complex represented by the following formula (I). 

Rare earth metal complex having phenanthroline compound as ligand

The present invention provides a novel compound having a phenanthroline structure represented by formula (I) or a salt thereof: 

Compounds having phenanthroline structure

Disclosed is a novel compound having an NPY Y5 receptor antagonistic activity. A compound represented by the formula:  

Urea derivative

Disclosed is a novel compound having an NPY Y5 receptor antagonistic activity. A compound represented by the formula: its pharmaceutically acceptable salt or solvate thereof,whereinX is hydrogen or the like,Y is a group of the formula: Z is &#x2014;NR&#x2014; or the like,Ris hydrogen or the like,Rand Rare each independently hydrogen or the like,n is 0 or 1,p is 0 to 6.

A piperidine derivative of the formula (I) is found to bind specifically with the NR1/NR2B receptor and usable as an analgesic (pain treatment drug). wherein X is OH or lower alkylsulfonyloxy; Ar is optionally substituted aryl or optionally substituted heteroaryl; n is an integer of 1 to 4; m is an integer of 0 to 1; Ris hydrogen; Ris OH or Rand Rtaken together may form a single bond; excluding that

Piperidine derivative having NMDA receptor antagonistic activity

A composition for use as an antiobestic agent and preventive or therapeutic agent for diabetes, containing a compound of the formula (I):wherein, A is substituted aryl or substituted heteroaryl with one or more group(s); (here, one of following groups is at least contained as the substituent: &#x2014;R&#x2014;R(Ris S, SO, SO, NR, NRSO(Ris hydrogen or lower alkyl) or lower alkylene); Ris optionally substituted aryl);

Cyclic amine derivatives and use thereof

The compounds of the present invention relates to tetrahydropyridine derivatives and have high affinity and specificity to .sigma. receptors, whereby these are thought to be effective for some psychoses.

Tetrahydropyridine derivatives

A compound of the formula: ##STR1## wherein n is an integer of from 2 to 6; and p and q each is an integer of 0 or 1, excluding the case where p is 0 when q is 1; or a pharmaceutically acceptable acid addition salt thereof. This compound has a high affinity and specificity to .sigma. receptors, and is thought to be effective for treatment of some psychoses.

A compound of the formula (I): ##STR1## wherein X.sup.1 nd X.sup.2 each independently represents lower alkyl, lower alkoxy or halogen or a pharmaceutically acceptable salt thereof, which is useful as an active ingredient for a pharmaceutical composition for treating antidepressant or aftereffects of cerebrovascular impairments.

Piperidine derivatives and process for preparation thereof

The present invention relates to tetrahydropyridine derivatives which have high affinity and specificity to .sigma. receptors, whereby these compounds are thought to be effective for treatment of some psychoses.

A compound of the formula: ##STR1## wherein R.sup.1 is hydrogen, or C.sub.1 14 C.sub.6 alkyl; n is an integer of from 2 to 3; Z.sup.1 is phenyl, benzyl, or isoxazolyl and each is optionally substituted by a halogen, a methoxy, or a methyl group; Z.sup.2 is hydrogen, C.sub.1 -C.sub.5 alkyl, allyl, unsubstituted phenyl, or phenyl substituted by halogen, methyl, or methoxy; or

Carbamoylpyrrolidone derivatives and drugs for senile dementia

Teirahydropyridine derivatives

A compound of the formula: ##STR1## (wherein R is phenoxy optionally substituted by a halogen, methoxy, or methyl group, ##STR2## one of A and B is ##STR3## and the other is &gt;CH.sub.2 ;

A compound of the formula: ##STR1## (wherein R is phenoxy optionally substituted by a halogen, methoxy, or methyl group, ##STR2## one of A and B is ##STR3## and the other is &gt;CH.sub.2 : R.sup.1 is hydrogen or C.sub.1 -C.sub.5 alkyl; Z.sup.1 is phenyl, benzyl, or isoxazolyl each optionally substituted by a halogen, methoxy, or methyl group; Z.sup.2 is hydrogen, C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.5 alkenyl, or phenyl optionally mono-, di-, or tri-substituted by a halogen, methoxy, or methyl group; or Z.sup.1 and Z.sup.2 taken together with the adjacent nitrogen atom may form 5-membered heterocyclic group; Z.sup.3 is C.sub.1 -C.sub.5 hydroxyalkyl, di(C.sub.1 -C.sub.5 alkyl)sulfamoyl, 6-membered heterocyclic group, phenyl, benzyl, or phenylsulfonyl each phenyl moiety of the last three members being optionally substituted by a halogen, methoxy, or methyl group; Z.sup.4 is phenyl optionally substituted by a halogen, methoxy, or methyl group or 5- or 6-membered heterocyclic group which is optionally substituted by a halogen, methoxy, or methyl group and which can be optionally condensed with a benzene ring; Z.sup.5 is thienyl or phenyl each optionally substituted by a halogen, methoxy, or methyl group; Z.sup.6 is thienyl or phenyl each optionally substituted by a halogen, methoxy, or methyl group; m is an integer from 0 to 2; n is an integer from 2 to 3) or its pharmaceutical acceptable acid addition salt being useful as a drug for senile dementia, psychotropic, or antiamnesia agent is provided through several routes.

Growing community of inventors

Kobe, Japan

Toshisada Yano